In this episode, Nilofer S. Azad, MD, and Kanwal Raghav, MD, discuss current and emerging uses of regorafenib and TAS-102 in later-line treatment of patients with mCRC, with topics including:

• Current use of regorafenib and TAS-102 monotherapy
• Combination therapy with regorafenib and PD-1 inhibitors
• Adding bevacizumab to TAS-102

Presenters:

Nilofer S. Azad, MD  
Professor, Oncology  
Sidney Kimmel Comprehensive Cancer Center  
Johns Hopkins University
Baltimore, Maryland  

Kanwal Raghav, MD
Associate Professor, GI Medical Oncology  
University of Texas MD Anderson Cancer Center
Houston, Texas  

Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Follow along with the slideset:
https://bit.ly/3NLejWe

Link to full program:
https://bit.ly/33yrIyh

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.